A Trial of Lopinavir-Ritonavir in Covid-19

被引：0
|
作者：
Carmona-Bayonas, Alberto [1 ]
Jimenez-Fonseca, Paula [2 ]
Castanon, Eduardo [3 ]
机构：
[1] Hosp Univ Morales Meseguer, Murcia, Spain
[2] Hosp Univ Cent Asturias, Oviedo, Spain
[3] Clin Univ Navarra, Madrid, Spain
来源：
NEW ENGLAND JOURNAL OF MEDICINE | 2020年 / 382卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
下载
收藏
页数：2
相关论文
共 50 条
  • [21] Lopinavir-Ritonavir Treatment for COVID-19 Infection in Intensive Care Unit Risk of Bradycardia
    Beyls, Christophe
    Martin, Nicolas
    Hermida, Alexis
    Abou-Arab, Osama
    Mahjoub, Yazine
    CIRCULATION-ARRHYTHMIA AND ELECTROPHYSIOLOGY, 2020, 13 (08): : E008798
  • [22] Lopinavir–ritonavir in severe COVID-19
    Hannah Stower
    Nature Medicine, 2020, 26 : 465 - 465
  • [23] Lopinavir-ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
    Horby, Peter W.
    Landray, Martin J.
    Mafham, Marion
    Bell, Jennifer L.
    Linsell, Louise
    Staplin, Natalie
    Emberson, Jonathan R.
    Palfreeman, Adrian
    Raw, Jason
    Elmahi, Einas
    Prudon, Benjamin
    Green, Christopher
    Carley, Simon
    Chadwick, David
    Davies, Matthew
    Wise, Matthew P.
    Baillie, J. Kenneth
    Chappell, Lucy C.
    Faust, Saul N.
    Jaki, Thomas
    Jeffery, Katie
    Lim, Wei Shen
    Montgomery, Alan
    Rowan, Kathryn
    Juszczak, Edmund
    Haynes, Richard
    LANCET, 2020, 396 (10259): : 1345 - 1352
  • [24] Acute Respiratory Distress Syndrome due to COVID-19 in India and efficacy of Indian Siddha drugs - A Trial of lopinavir-Ritonavir
    Rajeshbabu, P.
    Priadharsini, K.
    Riyaz, S. U. Mohammed
    Dhayalan, Manikandan
    JOURNAL OF PURE AND APPLIED MICROBIOLOGY, 2022, 16 (02): : 763 - 768
  • [25] High rate of major drug-drug interactions of lopinavir-ritonavir for COVID-19 treatment
    Macias, Juan
    Pinilla, Ana
    Lao-Dominguez, Francisco A.
    Corma, Anais
    Contreras-Macias, Enrique
    Gonzalez-Serna, Alejandro
    Gutierrez-Pizarraya, Antonio
    Fernandez-Fuertes, Marta
    Morillo-Verdugo, Ramon
    Trigo, Marta
    Real, Luis M.
    Pineda, Juan A.
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [26] In COVID-19, adding lopinavir-ritonavir to usual care did not shorten time to clinical improvement
    Yang, Philip
    Tekwani, Seema
    Martin, Greg S.
    ANNALS OF INTERNAL MEDICINE, 2020, 172 (12) : JC63 - JC63
  • [27] Statistical Issues and Lessons Learned From COVID-19 Clinical Trials With Lopinavir-Ritonavir and Remdesivir
    Yin, Guosheng
    Zhang, Chenyang
    Jin, Huaqing
    JMIR PUBLIC HEALTH AND SURVEILLANCE, 2020, 6 (03): : 231 - 241
  • [28] A Review of the Preclinical and Clinical Efficacy of Remdesivir, Hydroxychloroquine, and Lopinavir-Ritonavir Treatments against COVID-19
    Maciorowski, Dawid
    Idrissi, Samir Z. El
    Gupta, Yash
    Medernach, Brian J.
    Burns, Michael B.
    Becker, Daniel P.
    Durvasula, Ravi
    Kempaiah, Prakasha
    SLAS DISCOVERY, 2020, 25 (10) : 1108 - 1122
  • [29] Potentially fatal severe brady arrythmias related to Lopinavir-Ritonavir in a COVID 19
    Shree, Venkatesan
    Liew, Lydia Qi En
    Teo, Wei Wei
    Ting, Jeanette
    Liew, Mei Fong
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2021, 54 (01) : 133 - 135
  • [30] Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV
    Pulido, Federico
    Arribas, Jose R.
    Delgado, Rafael
    Cabrero, Esther
    Gonzalez-Garcia, Juan
    Perez-Elias, Maria J.
    Arranz, Alberto
    Portilla, Joaquin
    Pasquau, Juan
    Iribarren, Jose A.
    Rubio, Rafael
    Norton, Michael
    AIDS, 2008, 22 (02) : F1 - F9
12345